PortIO

Coming – August 25

A Game-changing Delivery Method For Chemo and other Medicines

Date and Time

August 25

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

Millions of patients rely on implanted ports, creating a $2B market. Unfortunately, current ports require regular flushing, depend on healthy veins, and carry ongoing risks of infection and occlusion.

PortIO is developing the first implantable intraosseous port for long-term vascular access. Instead of using veins, it delivers medications and fluids through the bone marrow into the central circulation. The device is designed to be maintenance-free, accessible like a traditional port, and available to patients who have exhausted conventional vascular options.

PortIO has completed and published its first-in-human study, is protected by seven issued patents, and is supported by PAVmed’s experienced medical device development platform.

Secure your space to hear from the PortIO leadership team about the regulatory pathway and the companies strategy for commercialization.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.